Cargando…
Quality of life in relapsing-remitting multiple sclerosis patients receiving CinnoVex compared with Avonex
OBJECTIVE: There is an increasing recognition among clinicians and researchers that the impact of chronic illnesses and their treatments must be assessed in terms of their quality of life (QoL) in addition to more traditional measures of clinical outcomes. The aim of this study was to compare the Qo...
Autores principales: | Hatam, Nahid, Bastani, Peivand, Shahtaheri, Rahil Sadat |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Medknow Publications & Media Pvt Ltd
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4966237/ https://www.ncbi.nlm.nih.gov/pubmed/27512709 http://dx.doi.org/10.4103/2279-042X.185725 |
Ejemplares similares
-
Cost Effectiveness Analysis of Avonex and CinnoVex in Relapsing Remitting MS
por: Najafi, Behzad, et al.
Publicado: (2015) -
Quality of Life Assessment in Patients with Multiple Sclerosis Receiving Interferon Beta-1a: A Comparative Longitudinal Study of Avonex and Its Biosimilar CinnoVex
por: Abolfazli, R., et al.
Publicado: (2012) -
Antibodies to Interferon beta in Patients with Multiple Sclerosis Receiving CinnoVex, Rebif, and Betaferon
por: Zare, Nasrin, et al.
Publicado: (2013) -
The efficacy and safety of oral disease-modifying therapies for relapsing-remitting multiple sclerosis: A systematic review
por: Shahtaheri, Rahil Sadat, et al.
Publicado: (2020) -
Assessment of Definitions of Sustained Disease Progression in Relapsing-Remitting Multiple Sclerosis
por: Healy, Brian C., et al.
Publicado: (2013)